Background
Methods
Database searching and screening process
Data extraction and quality assessment
Association test
Heterogeneity source analysis
Publication bias analysis
Results
Identification of eligible studies
First author | Year | NOS | Polymorphism | Case | Disease type | Control | Country | Ethnicity | Genotyping assay |
P
HWE
| ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A/A | A/B | B/B | A/A | A/B | B/B | |||||||||
Al-Ghnaniem [14] | 2007 | 7 | rs1801133 | 22 | 12 | 1 | adenomatous polyps | 41 | 29 | 6 | UK | Caucasian | PCR-RFLP | 0.784 |
rs1801133 | 11 | 3 | 3 | hyperplastic polyps | 41 | 29 | 6 | UK | Caucasian | PCR-RFLP | 0.784 | |||
rs1801131 | 18 | 12 | 5 | adenomatous polyps | 47 | 26 | 3 | UK | Caucasian | PCR-RFLP | 0.799 | |||
rs1801131 | 8 | 7 | 2 | hyperplastic polyps | 47 | 26 | 3 | UK | Caucasian | PCR-RFLP | 0.799 | |||
Ashktorab [15] | 2007 | 6 | rs1801133 | 18 | 4 | 0 | colorectal polyps | 30 | 5 | 0 | USA | Caucasian | PCR-RFLP | 0.649 |
Beckett [16] | 2015 | 5 | rs1801133 | 29 | 20 | 7 | adenomatous polyps | 88 | 91 | 18 | Australia | Caucasian | PCR-RFLP | 0.421 |
rs1801131 | 28 | 22 | 6 | adenomatous polyps | 101 | 83 | 13 | Australia | Caucasian | PCR-RFLP | 0.460 | |||
Chen [17] | 1998 | 8 | rs1801133 | 102 | 126 | 30 | adenomatous polyps | 323 | 324 | 66 | USA | Caucasian | PCR-RFLP | 0.234 |
Chiang [18] | 2015 | 7 | rs1801133 | 44 | 26 | 0 | adenomatous polyps | 91 | 73 | 18 | China | Asian | PCR-RFLP | 0.553 |
de Vogel [19] | 2011 | 6 | rs1801133 | 947 | 714 | 135 | adenomatous polyps | 4463 | 3563 | 708 | Norway | Caucasian | Real-time PCR | 0.933 |
Delgado [20] | 2001 | 8 | rs1801133 | 6 | 19 | 7 | adenomatous polyps | 34 | 52 | 24 | Mexico | Caucasian | PCR-RFLP | 0.625 |
Giovannucci [21] | 2003 | 6 | rs1801133 | 157 | 168 | 49 | adenomatous polyps | 299 | 325 | 101 | USA | Caucasian | PCR-RFLP | 0.401 |
rs1801131 | 186 | 165 | 24 | adenomatous polyps | 369 | 299 | 57 | USA | Caucasian | PCR-RFLP | 0.740 | |||
Goode [22] | 2004 | 7 | rs1801133 | 236 | 196 | 58 | adenomatous polyps | 259 | 238 | 67 | USA | Caucasian | PCR-RFLP | 0.281 |
Hazra [23] | 2007 | 7 | rs1801133 | 217 | 245 | 63 | adenomatous polyps | 229 | 232 | 64 | USA | Caucasian | NA | 0.658 |
rs1801131 | 278 | 211 | 48 | adenomatous polyps | 264 | 219 | 46 | USA | Caucasian | NA | 0.951 | |||
Hirose [24] | 2005 | 8 | rs1801133 | 182 | 203 | 67 | adenomatous polyps | 399 | 496 | 155 | Japan | Asian | PCR-RFLP | 0.966 |
Yi [8] | 2006 | 6 | rs1801133 | 5 | 5 | 4 | adenomatous polyps | 2 | 4 | 0 | Korea | Asian | PCR-RFLP | 0.221 |
rs1801131 | 10 | 3 | 1 | adenomatous polyps | 3 | 3 | 0 | Korea | Asian | PCR-RFLP | 0.414 | |||
Levine [25] | 2000 | 7 | rs1801133 | 256 | 163 | 52 | adenomatous polyps | 263 | 198 | 49 | USA | Caucasian | PCR-RFLP | 0.193 |
Lightfoot [26] | 2008 | 8 | rs1801133 | 135 | 132 | 41 | adenomatous polyps | 130 | 139 | 27 | UK | Caucasian | Taqman drug metabolizing genotyping assays | 0.238 |
rs1801131 | 155 | 124 | 29 | adenomatous polyps | 140 | 130 | 26 | UK | Caucasian | Taqman drug metabolizing genotyping assays | 0.590 | |||
Marugame [10] | 2000 | 8 | rs1801133 | 83 | 92 | 30 | adenomatous polyps | 89 | 105 | 26 | Japan | Asian | PCR-RFLP | 0.555 |
Mitrou [27] | 2006 | 7 | rs1801133 | 405 | 376 | 87 | adenomatous polyps | 402 | 407 | 89 | UK | Caucasian | PCR-RFLP | 0.340 |
rs1801131 | 383 | 375 | 104 | adenomatous polyps | 415 | 380 | 88 | UK | Caucasian | PCR-RFLP | 0.941 | |||
Pufulete [28] | 2003 | 7 | rs1801133 | 20 | 13 | 2 | adenomatous polyps | 41 | 29 | 6 | UK | Caucasian | PCR-RFLP | 0.784 |
rs1801131 | 18 | 12 | 5 | adenomatous polyps | 47 | 26 | 3 | UK | Caucasian | PCR-RFLP | 0.799 | |||
Ulrich [29] | 1999 | 9 | rs1801133 | 258 | 219 | 50 | adenomatous polyps | 303 | 269 | 73 | USA | Caucasian | PCR-RFLP | 0.260 |
Ulrich [30] | 2000 | 7 | rs1801133 | 98 | 72 | 26 | hyperplastic polyps | 297 | 258 | 71 | USA | Caucasian | PCR-RFLP | 0.192 |
van den [9] | 2005 | 7 | rs1801133 | 343 | 346 | 79 | adenomatous polyps | 325 | 305 | 79 | Netherlands | Caucasian | PCR-RFLP | 0.560 |
Williams [31] | 2013 | 7 | rs1801133 | 34 | 48 | 8 | adenomatous polyps | 44 | 42 | 9 | UK | Caucasian | PCR-RFLP | 0.822 |
Yamaji [32] | 2009 | 6 | rs1801133 | 263 | 325 | 124 | adenomatous polyps | 219 | 324 | 120 | Japan | Asian | TaqMan PCR | 0.993 |
rs1801131 | 452 | 228 | 32 | adenomatous polyps | 441 | 197 | 25 | Japan | Asian | TaqMan PCR | 0.609 |
Pooled analysis for MTHFR rs1801133
Comparison | Subgroup | Sample size | Test of association | |||
---|---|---|---|---|---|---|
Studies | Case/control | RRs (95% CIs) | z |
P
| ||
allele T vs. allele C | overall | 23 | 8321/17,731 | 0.98 (0.95, 1.01) | 1.42 | 0.156 |
UK | 6 | 1353/1517 | 0.99 (0.92, 1.07) | 0.14 | 0.886 | |
USA | 8 | 2863/4343 | 1.00 (0.95, 1.05) | 0.14 | 0.890 | |
Japan | 3 | 1369/1933 | 0.97 (0.91, 1.03) | 1.03 | 0.301 | |
Caucasian | 18 | 6868/15,610 | 0.99 (0.96, 1.02) | 0.86 | 0.391 | |
Asian | 5 | 1453/2121 | 0.95(0.90, 1.01) | 1.53 | 0.126 | |
hyperplastic polyps | 2 | 213/702 | 0.99 (0.84, 1.16) | 0.13 | 0.897 | |
adenomatous polyps | 20 | 8086/16,994 | 0.98 (0.95, 1.01) | 1.43 | 0.153 | |
TT vs. CC | overall | 22 | 8317/17,696 | 0.97 (0.90, 1.05) | 0.75 | 0.454 |
UK | 6 | 1353/1517 | 1.05 (0.85, 1.30) | 0.47 | 0.641 | |
USA | 7 | 2841/4308 | 1.01 (0.89, 1.14) | 0.11 | 0.913 | |
Japan | 3 | 1369/1933 | 0.95 (0.82, 1.11) | 0.61 | 0.540 | |
Caucasian | 17 | 6846/15,575 | 0.99 (0.91, 1.08) | 0.31 | 0.760 | |
Asian | 5 | 1453/2121 | 0.92(0.80, 1.07) | 1.06 | 0.291 | |
hyperplastic polyps | 2 | 213/702 | 1.13 (0.77, 1.65) | 0.62 | 0.532 | |
adenomatous polyps | 20 | 8086/16,994 | 0.97(0.77, 1.65) | 0.88 | 0.377 | |
CT vs. CC | overall | 23 | 8321/17,731 | 0.97 (0.94, 1.00) | 1.77 | 0.077 |
UK | 6 | 1353/1517 | 0.96 (0.89, 1.04) | 0.93 | 0.351 | |
USA | 8 | 2863/4343 | 0.99 (0.94, 1.04) | 0.44 | 0.663 | |
Japan | 3 | 1369/1933 | 0.94 (0.88, 1.01) | 1.67 | 0.094 | |
Caucasian | 18 | 6868/15,610 | 0.98 (0.95, 1.01) | 1.11 | 0.269 | |
Asian | 5 | 1453/2121 | 0.94 (0.87, 1.00) | 1.92 | 0.055 | |
hyperplastic polyps | 2 | 213/702 | 0.88 (0.73, 1.07) | 1.27 | 0.205 | |
adenomatous polyps | 20 | 8086/16,994 | 0.98 (0.95, 1.01) | 1.58 | 0.113 | |
CT + TT vs. CC | overall | 23 | 8321/17,731 | 0.98 (0.95, 1.00) | 1.76 | 0.079 |
UK | 6 | 1353/1517 | 0.98 (0.91, 1.06) | 0.66 | 0.511 | |
USA | 8 | 2863/4343 | 0.99 (0.95, 1.04) | 0.33 | 0.743 | |
Japan | 3 | 1369/1933 | 0.96 (0.91, 1.01) | 1.53 | 0.125 | |
Caucasian | 18 | 6868/15,610 | 0.98 (0.96, 1.01) | 1.08 | 0.280 | |
Asian | 5 | 1453/2121 | 0.95 (0.90, 1.00) | 1.95 | 0.052 | |
hyperplastic polyps | 2 | 213/702 | 0.94 (0.80, 1.09) | 0.82 | 0.414 | |
adenomatous polyps | 20 | 8086/16,994 | 0.98 (0.95, 1.00) | 1.65 | 0.098 | |
TT vs. CC + CT | overall | 22 | 8317/17,696 | 0.99 (0.92, 1.07) | 0.19 | 0.847 |
UK | 6 | 1353/1517 | 1.09 (0.87, 1.36) | 078 | 0.436 | |
USA | 7 | 2841/4308 | 1.02 (0.89, 1.16) | 0.23 | 0.822 | |
Japan | 3 | 1369/1933 | 1.01 (0.86, 1.18) | 0.08 | 0.934 | |
Caucasian | 17 | 6846/15,575 | 1.00 (0.91, 1.09) | 0.07 | 0.944 | |
Asian | 5 | 1453/2121 | 0.98 (0.83, 1.15) | 0.28 | 0.780 | |
hyperplastic polyps | 2 | 213/702 | 1.23 (0.83, 1.84) | 1.04 | 0.299 | |
adenomatous polyps | 20 | 8086/16,994 | 0.98(0.91, 1.84) | 0.39 | 0.696 | |
carrier T vs. carrier C | overall | 23 | 8321/17,731 | 0.99 (0.96, 1.01) | 0.99 | 0.322 |
UK | 6 | 1353/1517 | 0.99 (0.92, 1.07) | 0.21 | 0.831 | |
USA | 8 | 2863/4343 | 1.00 (0.95, 1.05) | 0.15 | 0.883 | |
Japan | 3 | 1369/1933 | 0.98 (0.91, 1.05) | 0.69 | 0.491 | |
Caucasian | 18 | 6868/15,610 | 0.99 (0.96, 1.02) | 0.64 | 0.523 | |
Asian | 5 | 1453/2121 | 0.97 (0.90, 1.03) | 0.99 | 0.322 | |
hyperplastic polyps | 2 | 213/702 | 0.98 (0.82, 1.16) | 0.26 | 0.793 | |
adenomatous polyps | 20 | 8086/16,994 | 0.99(0.96, 1.02) | 0.97 | 0.331 |
Pooled analysis for MTHFR rs1801131
Comparison | Subgroup | Sample size | Test of association | |||
---|---|---|---|---|---|---|
Studies | case/control | RRs (95% CIs) | z |
P
| ||
allele C vs. allele A | overall | 10 | 2951/3527 | 1.05 (0.99, 1.11) | 1.60 | 0.109 |
UK | 5 | 1257/1407 | 1.08 (0.99, 1.17) | 1.79 | 0.073 | |
Caucasian | 8 | 2225/2858 | 1.04 (0.98, 1.10) | 1.22 | 0.222 | |
adenomatous polyps | 9 | 2934/3451 | 1.04 (0.99, 1.10) | 1.48 | 0.138 | |
CC vs. AA | overall | 10 | 2951/3527 | 1.15 (0.98, 1.35) | 1.69 | 0.091 |
UK | 5 | 1257/1407 | 1.27 (1.02, 1.57) | 2.14 |
0.032
| |
Caucasian | 8 | 2225/2858 | 1.14 (0.96, 1.35) | 1.50 | 0.133 | |
adenomatous polyps | 9 | 2934/3451 | 1.14 (0.97, 1.34) | 1.58 | 0.114 | |
AC vs. AA | overall | 10 | 2951/3527 | 1.02 (0.96, 1.08) | 0.63 | 0.528 |
UK | 5 | 1257/1407 | 1.02 (0.93, 1.11) | 0.39 | 0.698 | |
Caucasian | 8 | 2225/2858 | 1.01 (0.95, 1.07) | 0.25 | 0.805 | |
adenomatous polyps | 9 | 2934/3451 | 1.02 (0.96, 1.08) | 0.56 | 0.576 | |
AC + CC vs. AA | overall | 10 | 2951/3527 | 1.03 (0.98, 1.08) | 1.13 | 0.258 |
UK | 5 | 1257/1407 | 1.04 (0.97, 1.12) | 1.08 | 0.279 | |
Caucasian | 8 | 2225/2858 | 1.02 (0.97, 1.08) | 0.72 | 0.471 | |
adenomatous polyps | 9 | 2934/3451 | 1.03 (0.98, 1.08) | 1.03 | 0.303 | |
CC vs. AA + AC | overall | 10 | 2951/3527 | 1.15 (0.97, 1.36) | 1.64 | 0.100 |
UK | 5 | 1257/1407 | 1.27 (1.02, 1.60) | 2.10 |
0.036
| |
Caucasian | 8 | 2225/2858 | 1.14 (0.96, 1.36) | 1.49 | 0.135 | |
adenomatous polyps | 9 | 2934/3451 | 1.14 (0.97, 1.35) | 1.55 | 0.122 | |
carrier C vs. carrier A | overall | 10 | 2951/3527 | 1.03 (0.97, 1.09) | 0.96 | 0.336 |
UK | 5 | 1257/1407 | 1.04 (0.96, 1.14) | 1.00 | 0.318 | |
Caucasian | 8 | 2225/2858 | 1.02 (0.96, 1.09) | 0.68 | 0.499 | |
adenomatous polyps | 9 | 2934/3451 | 1.03 (0.97, 1.09) | 0.88 | 0.376 |
Heterogeneity, publication bias and sensitivity analysis
polymorphism | Comparison | I2 | P value | Model | Begg’s test | Egger’s test | ||
---|---|---|---|---|---|---|---|---|
z |
P
| t |
P
| |||||
rs1801133 | allele T vs. allele C | 0.0% | 0.736 | Fixed | 0.69 | 0.492 | 0.46 | 0.651 |
TT vs. CC | 0.0% | 0.799 | Fixed | 0.90 | 0.367 | 0.75 | 0.463 | |
CT vs. CC | 0.0% | 0.705 | Fixed | 0.79 | 0.428 | −0.41 | 0.685 | |
CT + TT vs. CC | 0.0% | 0.725 | Fixed | 0.11 | 0.916 | −0.02 | 0.984 | |
TT vs. CC + CT | 0.0% | 0.790 | Fixed | 0.73 | 0.463 | 0.70 | 0.492 | |
carrier T vs. carrier C | 0.0% | 0.999 | Fixed | 0.32 | 0.751 | 0.27 | 0.787 | |
rs1801131 | allele C vs. allele A | 9.6% | 0.354 | Fixed | 1.16 | 0.245 | 1.41 | 0.195 |
CC vs. AA | 14.3% | 0.311 | Fixed | 1.52 | 0.128 | 1.96 | 0.085 | |
AC vs. AA | 0.0% | 0.800 | Fixed | 0.45 | 0.655 | −0.25 | 0.807 | |
AC + CC vs. AA | 0.0% | 0.623 | Fixed | 1.34 | 0.180 | 0.64 | 0.541 | |
CC vs. AA+AC | 8.3% | 0.366 | Fixed | 1.52 | 0.128 | 2.17 | 0.061 | |
carrier C vs. carrier A | 0.0% | 0.918 | Fixed | 0.98 | 0.325 | 1.04 | 0.327 |